EntryPoint Capital LLC Invests $812,000 in AtriCure, Inc. $ATRC

Key Points

• EntryPoint Capital LLC acquired 25,168 shares of AtriCure, Inc. for approximately $812,000, making it the firm's 13th largest position in its portfolio.
• Institutional investors collectively own 99.11% of AtriCure's stock, with notable increases from firms like Canada Pension Plan Investment Board, which raised its holdings by 756.1% in the last quarter.
• AtriCure recently reported a quarterly earnings beat, with $136.14 million in revenue and an earnings per share of -$0.02, exceeding analysts' expectations.

EntryPoint Capital LLC bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 25,168 shares of the medical device company's stock, valued at approximately $812,000. AtriCure accounts for approximately 0.4% of EntryPoint Capital LLC's investment portfolio, making the stock its 13th largest holding. EntryPoint Capital LLC owned 0.05% of AtriCure as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of ATRC. LPL Financial LLC boosted its position in shares of AtriCure by 5.4% in the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock worth $350,000 after purchasing an additional 584 shares during the last quarter. Invesco Ltd. boosted its stake in AtriCure by 0.8% during the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock worth $1,334,000 after acquiring an additional 334 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in AtriCure in the fourth quarter worth $3,716,000. Canada Pension Plan Investment Board raised its stake in AtriCure by 756.1% during the 4th quarter. Canada Pension Plan Investment Board now owns 35,100 shares of the medical device company's stock worth $1,073,000 after buying an additional 31,000 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in AtriCure by 24.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after acquiring an additional 136,015 shares during the period. 99.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ATRC shares. Wall Street Zen raised shares of AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. UBS Group reduced their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. JMP Securities reaffirmed a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a research report on Wednesday, April 30th. Needham & Company LLC boosted their target price on AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, July 30th. Finally, BTIG Research set a $54.00 price target on shares of AtriCure in a research note on Wednesday, July 30th. Nine equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $50.89.

Insider Activity

In other news, Director Sven Wehrwein sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $36.00, for a total transaction of $180,000.00. Following the transaction, the director owned 34,374 shares in the company, valued at approximately $1,237,464. This trade represents a 12.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Regina E. Groves sold 2,452 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $36.82, for a total value of $90,282.64. Following the completion of the sale, the director owned 33,715 shares of the company's stock, valued at $1,241,386.30. This trade represents a 6.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,452 shares of company stock valued at $445,333 over the last ninety days. 3.50% of the stock is currently owned by company insiders.

AtriCure Stock Performance

NASDAQ:ATRC traded up $0.2110 on Monday, hitting $37.8710. The company's stock had a trading volume of 95,841 shares, compared to its average volume of 581,479. AtriCure, Inc. has a one year low of $25.24 and a one year high of $43.11. The firm has a market capitalization of $1.88 billion, a P/E ratio of -49.20 and a beta of 1.61. The stock has a fifty day moving average of $33.05 and a two-hundred day moving average of $33.83. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The business had revenue of $136.14 million for the quarter, compared to analyst estimates of $130.17 million. During the same period in the previous year, the firm earned ($0.17) EPS. The firm's revenue was up 17.1% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. Research analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.